secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001711279-25-000082
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech launches VYJUVEK in Japan at NHI price of 2.955M yen per unit
-----------------------------------------------------------------------------

- Subsidiary Krystal Biotech Japan KK commenced commercial launch of VYJUVEK (beremagene geperpavec) on Oct 22, 2025.
- VYJUVEK added to Japan's National Health Insurance Drug Price List at 2,955,232.7 yen per unit.
- Drug indicated for dystrophic epidermolysis bullosa, a rare genetic skin disorder.
- Launch follows NHI listing, enabling patient access with government reimbursement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000082/0001711279-25-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000082/krys-20251022.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer